Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

FGF-23 Deficiency Impairs Hippocampal-Dependent Cognitive Function.

Laszczyk AM, Nettles D, Pollock TA, Fox S, Garcia ML, Wang J, Quarles LD, King GD.

eNeuro. 2019 Mar 22;6(2). pii: ENEURO.0469-18.2019. doi: 10.1523/ENEURO.0469-18.2019. eCollection 2019 Mar-Apr.

2.

Human GPRC6A Mediates Testosterone-Induced Mitogen-Activated Protein Kinases and mTORC1 Signaling in Prostate Cancer Cells.

Ye R, Pi M, Nooh MM, Bahout SW, Quarles LD.

Mol Pharmacol. 2019 May;95(5):563-572. doi: 10.1124/mol.118.115014. Epub 2019 Mar 20.

PMID:
30894404
3.

Fibroblast growth factor 23 and α-Klotho co-dependent and independent functions.

Quarles LD.

Curr Opin Nephrol Hypertens. 2019 Jan;28(1):16-25. doi: 10.1097/MNH.0000000000000467. Review.

PMID:
30451736
4.

Validation of a Novel Modified Aptamer-Based Array Proteomic Platform in Patients with End-Stage Renal Disease.

Han Z, Xiao Z, Kalantar-Zadeh K, Moradi H, Shafi T, Waikar SS, Quarles LD, Yu Z, Tin A, Coresh J, Kovesdy CP.

Diagnostics (Basel). 2018 Oct 8;8(4). pii: E71. doi: 10.3390/diagnostics8040071.

5.

Letter to the Editor: "Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH".

Han X, Quarles LD.

Endocrinology. 2018 Nov 1;159(11):3655-3656. doi: 10.1210/en.2018-00690. No abstract available.

PMID:
30247553
6.

Cardiovascular Interactions between Fibroblast Growth Factor-23 and Angiotensin II.

Pi M, Ye R, Han X, Armstrong B, Liu X, Chen Y, Sun Y, Quarles LD.

Sci Rep. 2018 Aug 17;8(1):12398. doi: 10.1038/s41598-018-30098-1.

7.

Changes With Lanthanum Carbonate, Calcium Acetate, and Phosphorus Restriction in CKD: A Randomized Controlled Trial.

Kovesdy CP, Lu JL, Wall BM, Gyamlani G, Naseer A, Wallick A, Han Z, Thomas F, Quarles LD, Jarmukli N.

Kidney Int Rep. 2018 Mar 23;3(4):897-904. doi: 10.1016/j.ekir.2018.03.011. eCollection 2018 Jul.

8.

Role of Fibroblast Growth Factor-23 in Innate Immune Responses.

Fitzpatrick EA, Han X, Xiao Z, Quarles LD.

Front Endocrinol (Lausanne). 2018 Jun 12;9:320. doi: 10.3389/fendo.2018.00320. eCollection 2018. Review.

9.

Computationally identified novel agonists for GPRC6A.

Pi M, Kapoor K, Ye R, Hwang DJ, Miller DD, Smith JC, Baudry J, Quarles LD.

PLoS One. 2018 Apr 23;13(4):e0195980. doi: 10.1371/journal.pone.0195980. eCollection 2018.

10.

GPCR6A Is a Molecular Target for the Natural Products Gallate and EGCG in Green Tea.

Pi M, Kapoor K, Ye R, Smith JC, Baudry J, Quarles LD.

Mol Nutr Food Res. 2018 Apr;62(8):e1700770. doi: 10.1002/mnfr.201700770. Epub 2018 Apr 14.

11.

Polycystin-1 interacts with TAZ to stimulate osteoblastogenesis and inhibit adipogenesis.

Xiao Z, Baudry J, Cao L, Huang J, Chen H, Yates CR, Li W, Dong B, Waters CM, Smith JC, Quarles LD.

J Clin Invest. 2018 Jan 2;128(1):157-174. doi: 10.1172/JCI93725. Epub 2017 Nov 27.

12.

Cardiovascular Effects of Renal Distal Tubule Deletion of the FGF Receptor 1 Gene.

Han X, Ross J, Kolumam G, Pi M, Sonoda J, King G, Quarles LD.

J Am Soc Nephrol. 2018 Jan;29(1):69-80. doi: 10.1681/ASN.2017040412. Epub 2017 Oct 9.

13.

Ensemble docking to difficult targets in early-stage drug discovery: Methodology and application to fibroblast growth factor 23.

Velazquez HA, Riccardi D, Xiao Z, Quarles LD, Yates CR, Baudry J, Smith JC.

Chem Biol Drug Des. 2018 Feb;91(2):491-504. doi: 10.1111/cbdd.13110. Epub 2017 Nov 3.

PMID:
28944571
14.

CRISPR/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model.

Ye R, Pi M, Cox JV, Nishimoto SK, Quarles LD.

J Exp Clin Cancer Res. 2017 Jun 28;36(1):90. doi: 10.1186/s13046-017-0561-x.

15.

GPRC6A: Jack of all metabolism (or master of none).

Pi M, Nishimoto SK, Quarles LD.

Mol Metab. 2016 Dec 21;6(2):185-193. doi: 10.1016/j.molmet.2016.12.006. eCollection 2017 Feb. Review.

16.

A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia.

Xiao Z, Riccardi D, Velazquez HA, Chin AL, Yates CR, Carrick JD, Smith JC, Baudry J, Quarles LD.

Sci Signal. 2016 Nov 22;9(455):ra113. Erratum in: Sci Signal. 2016 Dec 06;9(457):er3.

17.

The hypoxia-inducible factor-1α activates ectopic production of fibroblast growth factor 23 in tumor-induced osteomalacia.

Zhang Q, Doucet M, Tomlinson RE, Han X, Quarles LD, Collins MT, Clemens TL.

Bone Res. 2016 Jul 5;4:16011. doi: 10.1038/boneres.2016.11. eCollection 2016.

18.

Multiple faces of fibroblast growth factor-23.

Han X, Quarles LD.

Curr Opin Nephrol Hypertens. 2016 Jul;25(4):333-42. doi: 10.1097/MNH.0000000000000240. Review.

19.

Evidence for Osteocalcin Binding and Activation of GPRC6A in β-Cells.

Pi M, Kapoor K, Ye R, Nishimoto SK, Smith JC, Baudry J, Quarles LD.

Endocrinology. 2016 May;157(5):1866-80. doi: 10.1210/en.2015-2010. Epub 2016 Mar 23.

20.

FGF23 from bench to bedside.

Kovesdy CP, Quarles LD.

Am J Physiol Renal Physiol. 2016 Jun 1;310(11):F1168-74. doi: 10.1152/ajprenal.00606.2015. Epub 2016 Feb 10. Review.

21.

Conditional Deletion of Fgfr1 in the Proximal and Distal Tubule Identifies Distinct Roles in Phosphate and Calcium Transport.

Han X, Yang J, Li L, Huang J, King G, Quarles LD.

PLoS One. 2016 Feb 3;11(2):e0147845. doi: 10.1371/journal.pone.0147845. eCollection 2016.

22.

Joint mouse-human phenome-wide association to test gene function and disease risk.

Wang X, Pandey AK, Mulligan MK, Williams EG, Mozhui K, Li Z, Jovaisaite V, Quarles LD, Xiao Z, Huang J, Capra JA, Chen Z, Taylor WL, Bastarache L, Niu X, Pollard KS, Ciobanu DC, Reznik AO, Tishkov AV, Zhulin IB, Peng J, Nelson SF, Denny JC, Auwerx J, Lu L, Williams RW.

Nat Commun. 2016 Feb 2;7:10464. doi: 10.1038/ncomms10464.

23.

Counter-regulatory paracrine actions of FGF-23 and 1,25(OH)2 D in macrophages.

Han X, Li L, Yang J, King G, Xiao Z, Quarles LD.

FEBS Lett. 2016 Jan;590(1):53-67. doi: 10.1002/1873-3468.12040. Epub 2016 Jan 9.

24.

Enhanced FGF23 production in mice expressing PI3K-insensitive GSK3 is normalized by β-blocker treatment.

Fajol A, Chen H, Umbach AT, Quarles LD, Lang F, Föller M.

FASEB J. 2016 Feb;30(2):994-1001. doi: 10.1096/fj.15-279943. Epub 2015 Nov 2.

PMID:
26527066
25.

Structural and Functional Evidence for Testosterone Activation of GPRC6A in Peripheral Tissues.

Pi M, Kapoor K, Wu Y, Ye R, Senogles SE, Nishimoto SK, Hwang DJ, Miller DD, Narayanan R, Smith JC, Baudry J, Quarles LD.

Mol Endocrinol. 2015 Dec;29(12):1759-73. doi: 10.1210/me.2015-1161. Epub 2015 Oct 6.

26.

Membrane and integrative nuclear fibroblastic growth factor receptor (FGFR) regulation of FGF-23.

Han X, Xiao Z, Quarles LD.

J Biol Chem. 2015 Aug 14;290(33):20101. doi: 10.1074/jbc.A114.609230. No abstract available.

27.

Physiological mechanisms and therapeutic potential of bone mechanosensing.

Xiao Z, Quarles LD.

Rev Endocr Metab Disord. 2015 Jun;16(2):115-29. doi: 10.1007/s11154-015-9313-4. Review.

28.

Membrane and integrative nuclear fibroblastic growth factor receptor (FGFR) regulation of FGF-23.

Han X, Xiao Z, Quarles LD.

J Biol Chem. 2015 Apr 17;290(16):10447-59. doi: 10.1074/jbc.M114.609230. Epub 2015 Mar 9. Erratum in: J Biol Chem. 2015 Aug 14;290(33):20101.

29.

[FGF23 and the heart].

Ezumba I, Quarles LD, Kovesdy CP.

G Ital Nefrol. 2014 Nov-Dec;31(6). pii: gin/31.6.12. Review. Italian.

30.

Osteoblast-specific deletion of Pkd2 leads to low-turnover osteopenia and reduced bone marrow adiposity.

Xiao Z, Cao L, Liang Y, Huang J, Stern AR, Dallas M, Johnson M, Quarles LD.

PLoS One. 2014 Dec 2;9(12):e114198. doi: 10.1371/journal.pone.0114198. eCollection 2014.

31.

Osteocyte-specific deletion of Fgfr1 suppresses FGF23.

Xiao Z, Huang J, Cao L, Liang Y, Han X, Quarles LD.

PLoS One. 2014 Aug 4;9(8):e104154. doi: 10.1371/journal.pone.0104154. eCollection 2014.

32.

Activation of FGF-23 mediated vitamin D degradative pathways by cholecalciferol.

Alshayeb H, Showkat A, Wall BM, Gyamlani GG, David V, Quarles LD.

J Clin Endocrinol Metab. 2014 Oct;99(10):E1830-7. doi: 10.1210/jc.2014-1308. Epub 2014 Jun 24.

33.

Association of body mass index with outcomes in patients with CKD.

Lu JL, Kalantar-Zadeh K, Ma JZ, Quarles LD, Kovesdy CP.

J Am Soc Nephrol. 2014 Sep;25(9):2088-96. doi: 10.1681/ASN.2013070754. Epub 2014 Mar 20.

34.

Novel bone endocrine networks integrating mineral and energy metabolism.

Pi M, Quarles LD.

Curr Osteoporos Rep. 2013 Dec;11(4):391-9. doi: 10.1007/s11914-013-0178-8. Review.

35.

Calcium regulates FGF-23 expression in bone.

David V, Dai B, Martin A, Huang J, Han X, Quarles LD.

Endocrinology. 2013 Dec;154(12):4469-82. doi: 10.1210/en.2013-1627. Epub 2013 Oct 18.

36.

Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study.

Kovesdy CP, Bleyer AJ, Molnar MZ, Ma JZ, Sim JJ, Cushman WC, Quarles LD, Kalantar-Zadeh K.

Ann Intern Med. 2013 Aug 20;159(4):233-42. doi: 10.7326/0003-4819-159-4-201308200-00004.

37.

The role of fibroblast growth factor-23 in cardiorenal syndrome.

Kovesdy CP, Quarles LD.

Nephron Clin Pract. 2013;123(3-4):194-201. doi: 10.1159/000353593. Epub 2013 Aug 6. Review.

38.

Fibroblast growth factor-23: what we know, what we don't know, and what we need to know.

Kovesdy CP, Quarles LD.

Nephrol Dial Transplant. 2013 Sep;28(9):2228-36. doi: 10.1093/ndt/gft065. Epub 2013 Apr 25. Review.

39.

A systems biology preview of the relationships between mineral and metabolic complications in chronic kidney disease.

Quarles LD.

Semin Nephrol. 2013 Mar;33(2):130-42. doi: 10.1016/j.semnephrol.2012.12.014. Review.

40.

Survival advantage in black versus white men with CKD: effect of estimated GFR and case mix.

Kovesdy CP, Quarles LD, Lott EH, Lu JL, Ma JZ, Molnar MZ, Kalantar-Zadeh K.

Am J Kidney Dis. 2013 Aug;62(2):228-35. doi: 10.1053/j.ajkd.2012.12.012. Epub 2013 Jan 29.

41.

Reducing cardiovascular mortality in chronic kidney disease: something borrowed, something new.

Quarles LD.

J Clin Invest. 2013 Feb;123(2):542-3. doi: 10.1172/JCI67203. Epub 2013 Jan 9. Review.

42.

Chronic kidney disease and diabetes mellitus predict resistance to vitamin D replacement therapy.

Alshayeb HM, Wall BM, Showkat A, Quarles LD, Mangold T.

Am J Med Sci. 2013 Apr;345(4):314-320. doi: 10.1097/MAJ.0b013e31826af2d3.

43.

Conditional mesenchymal disruption of pkd1 results in osteopenia and polycystic kidney disease.

Qiu N, Xiao Z, Cao L, David V, Quarles LD.

PLoS One. 2012;7(9):e46038. doi: 10.1371/journal.pone.0046038. Epub 2012 Sep 21.

44.

A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model.

Dai B, David V, Martin A, Huang J, Li H, Jiao Y, Gu W, Quarles LD.

PLoS One. 2012;7(9):e44161. doi: 10.1371/journal.pone.0044161. Epub 2012 Sep 6.

45.

Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice.

Martin A, David V, Li H, Dai B, Feng JQ, Quarles LD.

Mol Endocrinol. 2012 Nov;26(11):1883-95. doi: 10.1210/me.2012-1062. Epub 2012 Aug 28.

46.

GPRC6A mediates the effects of L-arginine on insulin secretion in mouse pancreatic islets.

Pi M, Wu Y, Lenchik NI, Gerling I, Quarles LD.

Endocrinology. 2012 Oct;153(10):4608-15. Epub 2012 Aug 7.

47.

Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells.

Dreaden EC, Gryder BE, Austin LA, Tene Defo BA, Hayden SC, Pi M, Quarles LD, Oyelere AK, El-Sayed MA.

Bioconjug Chem. 2012 Aug 15;23(8):1507-12. doi: 10.1021/bc300158k. Epub 2012 Jul 12.

48.

Assessment of 24,25(OH)2D levels does not support FGF23-mediated catabolism of vitamin D metabolites.

Dai B, David V, Alshayeb HM, Showkat A, Gyamlani G, Horst RL, Wall BM, Quarles LD.

Kidney Int. 2012 Nov;82(10):1061-70. doi: 10.1038/ki.2012.222. Epub 2012 Jun 27.

49.

Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease.

Quarles LD.

Exp Cell Res. 2012 May 15;318(9):1040-8. doi: 10.1016/j.yexcr.2012.02.027. Epub 2012 Mar 7. Review.

50.

Evidence for FGF23 involvement in a bone-kidney axis regulating bone mineralization and systemic phosphate and vitamin D homeostasis.

Martin A, Quarles LD.

Adv Exp Med Biol. 2012;728:65-83. doi: 10.1007/978-1-4614-0887-1_4. Review.

Supplemental Content

Loading ...
Support Center